First Time Loading...

Fate Therapeutics Inc
NASDAQ:FATE

Watchlist Manager
Fate Therapeutics Inc Logo
Fate Therapeutics Inc
NASDAQ:FATE
Watchlist
Price: 7.34 USD Market Closed
Updated: Mar 29, 2024

Intrinsic Value

FATE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. [ Read More ]

The intrinsic value of one FATE stock under the Base Case scenario is 0.6 USD. Compared to the current market price of 7.34 USD, Fate Therapeutics Inc is Overvalued by 92%.

Key Points:
FATE Intrinsic Value
Base Case
0.6 USD
Overvaluation 92%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Fate Therapeutics Inc

Backtest FATE Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling FATE stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Fate Therapeutics Q4 Performance and Outlook
2023-Q4 Earnings Call

Fate Therapeutics Q4 Performance and Outlook

Fate Therapeutics has seen its revenue drop from $44.4 million to $1.7 million in Q4 compared to the prior year, mainly reflecting collaboration with Ono Pharmaceutical. R&D expenses fell by over 60% to $31.8 million, attributed to reduced salaries and benefits after restructuring, while G&A expenses decreased by 17% to $17.9 million. Despite this, the company maintains a strong financial position with $316 million in cash and investments. The net loss for the quarter was $44.1 million, or $0.45 per share. Updates on FT522 without conditioning chemotherapy and the multiple myeloma program FT576 are expected in the second half of 2024 and mid-year, respectively.

Financials

Balance Sheet Decomposition
Fate Therapeutics Inc

Current Assets 331.5m
Cash & Short-Term Investments 315.2m
Receivables 1.8m
Other Current Assets 14.5m
Non-Current Assets 174.7m
Long-Term Investments 980k
PP&E 158.5m
Other Non-Current Assets 15.2m
Current Liabilities 39.1m
Accounts Payable 4.7m
Accrued Liabilities 33.7m
Other Current Liabilities 685k
Non-Current Liabilities 98.7m
Other Non-Current Liabilities 98.7m
Efficiency

Earnings Waterfall
Fate Therapeutics Inc

Revenue
63.5m USD
Operating Expenses
-254m USD
Operating Income
-190.5m USD
Other Expenses
29.6m USD
Net Income
-160.9m USD

Free Cash Flow Analysis
Fate Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

FATE Profitability Score
Profitability Due Diligence

Fate Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROIC is Increasing
ROE is Increasing
Negative 1-Year Revenue Growth
19/100
Profitability
Score

Fate Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

FATE Solvency Score
Solvency Due Diligence

Fate Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
60/100
Solvency
Score

Fate Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FATE Price Targets Summary
Fate Therapeutics Inc

Wall Street analysts forecast FATE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FATE is 7.68 USD with a low forecast of 2.02 USD and a high forecast of 12.6 USD.

Lowest
Price Target
2.02 USD
72% Downside
Average
Price Target
7.68 USD
5% Upside
Highest
Price Target
12.6 USD
72% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

FATE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

FATE Price
Fate Therapeutics Inc

1M 1M
+4%
6M 6M
+246%
1Y 1Y
+32%
3Y 3Y
-90%
5Y 5Y
-58%
10Y 10Y
-25%
Annual Price Range
7.34
52w Low
1.65
52w High
8.35
Price Metrics
Average Annual Return 63.88%
Standard Deviation of Annual Returns 201.51%
Max Drawdown -99%
Shares Statistics
Market Capitalization 723.9m USD
Shares Outstanding 99 237 504
Percentage of Shares Shorted 17.4%

FATE Return Decomposition
Main factors of price return

What is price return decomposition?

FATE News

Other Videos

Last Important Events
Fate Therapeutics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Fate Therapeutics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Fate Therapeutics Inc Logo
Fate Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

723.9m USD

Dividend Yield

0%

Description

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 449 full-time employees. The company went IPO on 2013-10-01. The firm is focused on the development of programmed cellular immunotherapies for patients with cancer. The company uses human induced pluripotent stem cells (iPSCs) generated from its proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The firm is advancing a pipeline of programmed cellular immunotherapies, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master iPSC lines for the treatment of cancer. The firm's product pipeline includes FT596, FT538, FT576, FT536, FT573, FT819, FT500 and FT516. FT516 is an investigational off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel CD16 (hnCD16) Fc receptor. FT596 is an investigational off-the-shelf CAR NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.

Contact

CALIFORNIA
San Diego
12278 Scripps Summit Drive
+18588751803.0
http://fatetherapeutics.com/

IPO

2013-10-01

Employees

449

Officers

Founder, CEO, President & Director
Mr. J. Scott Wolchko
Chief Financial Officer
Mr. Edward J. Dulac III
General Counsel & Corporate Secretary
Ms. Cindy R. Tahl
Chief Research & Development Officer
Dr. Bahram Valamehr Ph.D.
Senior Vice President of Corporate Development
Mr. Jim Beitel M.B.A.
Senior Vice President of Regulatory & Quality
Dr. Jerome Bressi Ph.D.
Show More
Senior VP of Clinical Development
Dr. Barbara Hickingbottom
Show Less

See Also

Discover More
What is the Intrinsic Value of one FATE stock?

The intrinsic value of one FATE stock under the Base Case scenario is 0.6 USD.

Is FATE stock undervalued or overvalued?

Compared to the current market price of 7.34 USD, Fate Therapeutics Inc is Overvalued by 92%.